C

CJ 바이오사이언스

311690KOSDAQ자연과학 및 공학 연구개발업

49.5 / 100

Reference Date: 2026-04-13

Financial Score19.0 / 40
News Sentiment12.5 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but Revenue is on a declining trend. Slightly down 4.8% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

CJ BioScience operates core businesses including AI-powered microbiome analysis platforms (Ez-Mx®) for drug development, microbial genome analysis solutions, and health & wellness services (e.g., GUT INSIDE, SMILE GUT). The company has strategically shifted focus toward health & wellness, expanding consumer-accessible AI-based gut health diagnostic services in 2025. The majority of revenue comes from its microbiome genome analysis platform, EzBioCloud.

Number of Employees

102people

Average Salary

79.3M KRW

Score Calculation Basis

Detailed Financial Score

PER
Industry Average 120.074.0Point
PBR
1.87Industry Average 3.827.0Point

Half of industry avg (excellent)

ROE
-36.54Industry Average -32.113.5Point

In line with industry avg

Debt Ratio
7.72Industry Average 7.522.0Point

Higher than industry avg (caution)

Trend 2023~20252.5 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼15.7% (2-year basis)

Operating Profit Growth Rate
2.5 / 3

Avg ▲10.4% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -39.5% (improving, 3yr)

Detailed News Sentiment

3 totalPositive 1Neutral 2Negative 0Average Sentiment Score 50

Detailed Momentum

52-week position1.0Point

Near 52w low (6%, downtrend)

Current 7,680Won52-week high 11,30052-week low 7,420
1-month return2.0Point

1m -4.83% (slight drop)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0
  • Neutral정기주주총회결과2026-03-26
  • Neutral사업보고서 (2025.12)2026-03-16
  • Neutral감사보고서제출2026-03-16